Beihai Gofar Marine Biological Industry Co Ltd - Asset Resilience Ratio
Beihai Gofar Marine Biological Industry Co Ltd (600538) has an Asset Resilience Ratio of 0.13% as of June 2021. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Beihai Gofar Marine Biological Industry (600538) working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2002–2020)
This chart shows how Beihai Gofar Marine Biological Industry Co Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Beihai Gofar Marine Biological Industry asset portfolio.
Liquid Assets Composition Over Time
This chart breaks down Beihai Gofar Marine Biological Industry Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore 600538 strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥1.29 Million | 0.13% |
| Total Liquid Assets | CN¥1.29 Million | 0.13% |
Asset Resilience Insights
- Limited Liquidity: Beihai Gofar Marine Biological Industry Co Ltd maintains only 0.13% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Beihai Gofar Marine Biological Industry Co Ltd Industry Peers by Asset Resilience Ratio
Compare Beihai Gofar Marine Biological Industry Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Qinghai Salt Lake Industry Co.Ltd
SHE:000792 |
Agricultural Inputs | 0.01% |
|
Shaanxi Meibang Pharmaceutical Group Co Ltd
SHG:605033 |
Agricultural Inputs | 18.19% |
|
Boa Safra Sementes S.A
SA:SOJA3 |
Agricultural Inputs | 23.11% |
|
Soquicom
SN:SOQUICOM |
Agricultural Inputs | 0.81% |
|
Verde Agritech PLC
TO:NPK |
Agricultural Inputs | 4.60% |
|
Terragen Holdings Ltd
AU:TGH |
Agricultural Inputs | 1.39% |
|
Neurizer Ltd
AU:NRZ |
Agricultural Inputs | 0.10% |
|
Insumos Agroquimicos SA
BA:INAG |
Agricultural Inputs | 1.46% |
Annual Asset Resilience Ratio for Beihai Gofar Marine Biological Industry Co Ltd (2002–2020)
The table below shows the annual Asset Resilience Ratio data for Beihai Gofar Marine Biological Industry Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2020-12-31 | 1.52% | CN¥16.15 Million ≈ $2.36 Million |
CN¥1.07 Billion ≈ $155.95 Million |
-22.06pp |
| 2018-12-31 | 23.58% | CN¥180.00 Million ≈ $26.34 Million |
CN¥763.38 Million ≈ $111.71 Million |
+0.15pp |
| 2017-12-31 | 23.43% | CN¥182.00 Million ≈ $26.63 Million |
CN¥776.75 Million ≈ $113.66 Million |
+2.55pp |
| 2016-12-31 | 20.88% | CN¥200.00 Million ≈ $29.27 Million |
CN¥957.71 Million ≈ $140.14 Million |
+4.62pp |
| 2015-12-31 | 16.26% | CN¥160.00 Million ≈ $23.41 Million |
CN¥984.02 Million ≈ $143.99 Million |
+16.18pp |
| 2006-12-31 | 0.08% | CN¥1.00 Million ≈ $146.33K |
CN¥1.30 Billion ≈ $190.39 Million |
+0.06pp |
| 2005-12-31 | 0.02% | CN¥250.02K ≈ $36.59K |
CN¥1.27 Billion ≈ $185.50 Million |
-0.05pp |
| 2003-12-31 | 0.07% | CN¥492.57K ≈ $72.08K |
CN¥740.21 Million ≈ $108.32 Million |
-0.11pp |
| 2002-12-31 | 0.18% | CN¥421.53K ≈ $61.68K |
CN¥235.22 Million ≈ $34.42 Million |
-- |
About Beihai Gofar Marine Biological Industry Co Ltd
Beihai Gofar Chuanshan Biological Co., Ltd., together with its subsidiaries, distributes pharmaceutical products in China. It operates through Pharmaceutical Distribution; Pharmaceutical Manufacturing; DNA Testing Equipment, Consumables and Testing Services; and Others segments. The company wholesales and retails pharmaceutical products through hospitals, clinics, other medical institutions, phar… Read more